Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for protein-protein interfaces.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes extensive molecular simulations of the target protein alone and in complex with its most relevant partner proteins, followed by ensemble virtual screening that considers conformational mobility in both free and complex states. Potential binding pockets are examined on the protein-protein interaction interface and in distant allosteric sites to cover all possible mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q16637

UPID:
SMN_HUMAN

ALTERNATIVE NAMES:
Component of gems 1; Gemin-1

ALTERNATIVE UPACC:
Q16637; A8K0V4; Q13119; Q549U5; Q96J51

BACKGROUND:
Survival Motor Neuron protein, known alternatively as Component of gems 1 or Gemin-1, is integral to snRNP assembly, influencing spliceosome construction and mRNA splicing. Its activity is vital for the proper functioning of motor and proprioceptive neurons.

THERAPEUTIC SIGNIFICANCE:
The protein's association with Spinal Muscular Atrophy types 1 through 4 highlights its therapeutic significance. Targeting the underlying genetic variants affecting SMN1 offers a promising avenue for developing SMA treatments, potentially improving patient outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.